Published in final edited form as:

J Am Chem Soc. 2006 September 13; 128(36): 11799–11807. doi:10.1021/ja0632862.

Total Synthesis of Piericidin A1 and B1 and Key Analogues

Martin J. Schnermann^a, F. Anthony Romero^a, Inkyu Hwang^a, Eiko Nakamaru-Ogiso^b, Takao Yagi^b, and Dale L. Boger^a

^aDepartment of Chemistry and the Skaggs Institute for Chemical Biology The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

^bDepartments of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

Abstract

Full details of the total synthesis of piericidin A1 and B1 and its extension to the preparation of a series of key analogues are described including *ent*-piericidin A1 (*ent*-**1**), 4'-deshydroxypiericidin A1 (**58**), 5'-desmethylpiericidin A1 (**73**), 4'-deshydroxy-5'-desmethylpiericidin A1 (**75**), and the corresponding analogues **51**, **59**, **76**, and **77** bearing a simplified farnesyl side chain. The evaluation of these key analogues, along with those derived from their further functionalizations, permitted a scan of the key structural features providing new insights into the role of the substituents found in both the pyridyl core as well as the side chain. A strategic late stage heterobenzylic Stille cross-coupling reaction of the pyridyl core with the fully elaborated side chain permitted ready access to the analogues in which each half of the molecule could be systematically and divergently modified. The pyridyl cores were assembled enlisting inverse electron demand Diels–Alder reactions of *N*-sulfonyl-1-azabutadienes while key elements of side chain syntheses include an anti selective asymmetric aldol to install the C9 and C10 relative and absolute stereochemistry (for natural and *ent*-**1**) and a modified Julia olefination for formation of the C5–C6 trans double bond with convergent assemblage of the side chains.

Introduction

Piericidin A1 (**1**) is the prototypical member of an important class of biologically active natural products isolated from *Streptomyces mobaraensis* and *pactam* (Figure 1).¹ The most widely recognized biological target of **1** and members of this natural product class is the mitochondrial electron transport chain protein NADH-ubiquinone reductase (Complex I) and the piericidins are among the most potent inhibitors identified to date ($K_i = 0.6$ – 1.0 nM). Complex I mediates the transfer of protons into the intermembrane space of the mitochondria through a NADH driven reduction of ubiquinone (**3**) to its hydroquinone² and the piericidins have contributed extensively to the elucidation of the properties of this highly complex enzyme.³ Although initially investigated as an insecticide, the piericidins have been found to exhibit a range of promising biological activity. Some piericidins have been shown to exhibit antimicrobial and antifungal activity with minimum inhibitory concentrations as low as 6 μ g/mL, while others have been shown to block antibody formation (inhibit the immune response to antigen exposure) at the remarkably low concentrations of 100 pg/mL.^{4–6} Most recently, **1** was identified as a potent inhibitor of interleukin-2 (IL-2) production in a cellular functional assay.⁷ IL-2 is a regulator of many essential immune responses and its over-expression is linked to

E-mail: boger@scripps.edu.

Supporting Information Available. Full experimental details are provided in the supporting information. This material is available free of charge via the Internet at <http://pubs.acs.org>.

malignancy, autoimmune diseases, organ transplant rejection, and renal allograft rejection. Additionally, and of the most significance to our own interests, **1** was identified as a highly selective antitumor agent with greater selectivity and potency than the comparison standard mitomycin C.⁸ In fact, a number of Complex I inhibitors from the rotenoid class of natural products, of which rotenone (**4**) is the prototypical member, have received considerable attention as anti-cancer agents and have exhibited efficacious *in vivo* activity in animal models.⁹ Although the precise mechanism responsible for the selective antitumor activity of such Complex I inhibitors has not been fully elucidated, several explanations have been advanced.¹⁰⁻¹³

Despite this array of potentially useful biological activity, no total synthesis of a member of this large class of natural products had been described prior to our initial disclosure.¹⁴ Shortly following this preliminary disclosure, Phillips and Keaton reported a complementary total synthesis of (–)-7-demethylpiericidin A1, a natural product closely related to **1**.¹⁵ In earlier efforts directed at this family, a racemic synthesis of analogues incorporating the full side chain, but a substituted benzene in place of the substituted pyridine of **1** has been disclosed, and an asymmetric synthesis of the C6–C13 segment of the side chain bearing the most recent stereochemical assignment (9*R*,10*R*) has been reported.^{16,17} In addition, the preparation of several analogues bearing simplified side chains have been disclosed.¹⁸⁻²⁰ Notably, and at the time that our work and that of Phillips was conducted, the originally assigned absolute stereochemistry²¹ of the side chain substituents of **1** had been challenged, reassigned, and remained to be unambiguously established.^{22,23}

Herein we provide full details of this synthesis of piericidin A1 and B1 by an approach that, like that of Phillips, established the absolute stereochemistry of the natural products and report its subsequent extension to the synthesis and evaluation of a series of key analogues (Figure 2). Central to the approach is the use of an inverse electron demand Diels–Alder reaction of a *N*-sulfonyl-1-aza-1,3-butadiene²⁴ with tetramethoxyethene²⁵ followed by Lewis acid-promoted aromatization for assemblage of the functionalized pyridine core.²⁶ Based on prior work with such systems, an azadiene bearing an additional strong electron-withdrawing group at C-2 would be expected to facilitate the Diels–Alder reaction such that the fully substituted and sensitive tetramethoxyethene could be anticipated to react under mild conditions. Additional key elements of the approach include the use of an asymmetric anti-aldol reaction to install the C9 and C10 relative and absolute stereochemistry, a modified Julia olefination for formation of the C5–C6 trans double bond with convergent assemblage of the side chain, and a surprisingly effective penultimate heterobenzylic Stille cross-coupling reaction of the pyridyl core with the fully elaborated side chain. Notably, the strategic late stage coupling of the fully functionalized pyridyl core with the fully elaborated side chain was anticipated to permit access to analogues in which either half of the molecule could be systematically and divergently²⁷ altered.

Thus, in addition to the natural products, we were especially interested in the synthesis of a series of analogues that would define the key features of this class of molecules responsible for their biological activity. Of particular interest was the suggestion that the 4-hydroxypyridine of **1**, as the pyridone tautomer, mimics the quinone of ubiquinone (coenzyme Q, **3**) with the side chain of **1** mimicking the prenyl chain. This apparent structural relationship has been confirmed through their competitive binding against Complex I. However, competitive substrate binding may not fully account for the inhibitory activity as **1** binds to at least two sites on Complex I; one competitive with coenzyme Q and one competitive with rotenone, neither of which are competitive with each other.^{3,28,29} Moreover and although piericidin A1 competitively blocks the binding of endogenous ubiquinone (the most upstream inhibition site of the inhibitor-binding domain of Complex I), the majority of specific Complex I inhibitors exhibit noncompetitive or uncompetitive behavior against the artificial substrate n-

decylubiquinone.³⁰ Thus, the absence of mutual exclusivity between the inhibitor and the ubiquinone binding sites presents a major challenge in identifying the actual Complex I sites of action of these potent agents and their relation to the ubiquinone reduction sites.³¹ Thus, the exact role of the apparent structural homology between **1** and **3** has not been fully established. It was envisioned that a carefully constructed series of analogues could be used to probe such questions.

Total Synthesis of Piericidin A1 and Piericidin B1

Our initial objective was to use the Diels–Alder reaction of tetramethoxyethene with *N*-sulfonyl-1-azadiene **6**³² bearing a C4 benzyloxy substituent permitting direct access to the fully substituted pyridine upon base-catalyzed aromatization (Scheme 1). Conversion of the ketone **5** to the requisite azadiene **6** (PhSO₂NH₂, TiCl₄, 0 °C, 1 h, 20%) proved problematic providing **6** in low yields. Similarly, the alternative two-step approach enlisting the oxime **7** did not prove viable. More significantly, *N*-sulfonyl-1-azadiene **6** failed to react with either **8**²⁵ or ethyl vinyl ether in an initial survey of reaction conditions.

Based on this initial finding, it was decided that the C4' hydroxyl could be installed following the Diels–Alder and aromatization sequence permitting the use of the less substituted and more electron-deficient *N*-sulfonyl-1-azadiene **12** (Scheme 2). This key *N*-sulfonyl-1-aza-1,3-butadiene was accessed through a two-step sequence initiated by oxime formation of the ketone **10**³³ (NH₂OH–HCl, EtOH, 25 °C, 18 h, 96%). Treatment of the oxime **11** with Et₃N and methylsulfinyl chloride led to initial formation of the *O*-methanesulfinate and its in situ homolytic rearrangement to give sulfonylimine **12** (CH₃SOC₂Cl, Et₃N, CH₂Cl₂, 0 °C, 20 min).³⁴ Direct conversion of the ketone **10** to **12** (MeSO₂NH₂, TiCl₄, 0 °C, 1 h, 40%) was also possible, but was not pursued due to lower initial conversions. Treatment of **12** with **8** (toluene, 50 °C, 18 h, 64% for 2 steps from **11**) smoothly afforded the [4 + 2] cycloadduct **13**. As anticipated, the electron-deficient *N*-sulfonyl-1-azadiene **12** substituted with the additional C2 electron-withdrawing substituent^{26a,b} participated in the Diels–Alder reaction with the electron-rich dienophile **8** at or near room temperature even though **8** is tetrasubstituted and sterically demanding. Despite its potential hydrolytic lability, the cycloadduct **13** (mp 116–118 °C) proved remarkably robust being isolated by conventional chromatography on SiO₂ and its structure was confirmed by single crystal X-ray diffraction (Figure 3).³⁵ Although efforts to induce aromatization of **13** under a variety of basic conditions were surprisingly unsuccessful, having been anticipated to result from a well-precedented C4 deprotonation and elimination of a C3 methoxy group followed by methanesulfonyl deprotonation and loss of sulfene concurrent with C2 methoxy elimination,³⁶ the use of the Lewis acid BF₃·OEt₂ cleanly affected this transformation (CH₂Cl₂, 0 °C, 1 h, 88%). Reduction of the ethyl ester **14** with DIBALH (CH₂Cl₂, 0 °C, 1 h, 92%) followed by protection of the resulting alcohol **15** as its TIPS ether provided **16** (TIPSCl, imidazole, DMF, 25 °C, 18 h, 95%). We had envisioned that directed lithiation of the pyridyl C4 position followed by a borylation/oxidation sequence would serve to introduce the remaining oxygen substituent.³⁷ Thus, treatment of **16** with excess base followed by trimethylborate (5 equiv of BuLi, 6 equiv of B(OMe)₃, –78 °C, 1 h, 88%), and oxidative cleavage of the resulting aryl boronate ester provided the *C*-silylated product **17** resulting from both the desired C4' hydroxylation and a competitive reverse Brook rearrangement of the benzylic TIPS ether under the strongly basic conditions.³⁸ This unexpected result was confirmed with an X-ray analysis of **17** (Figure 3).³⁵ The use of fewer equivalents of base resulted in the product arising only from silyl migration indicating that the primary site of the deprotonation under these conditions was the benzylic center, and the use of alternative silyl ether protecting groups (TBS and TBDPS) or the free alcohol **15** itself resulted in lower yields of the diol **19**. The deprotection of **17** proceeded cleanly and, interestingly, through the *O*-silylated intermediate **18** resulting from an initial Brook rearrangement, to give **19** (Bu₄NF, THF, 25 °C, 36 h, 96%). Thus, if the desilylation reaction

was quenched after 30 min versus 36 h, the intermediate *O*-silyl ether **18** was isolated in yields as high as 80%, and its resubjection to the reaction conditions for a longer period resulted in clean conversion on to **19**. Conversion of **19** to the heterobenzylic bromide **20** (1 equiv of CBr₄, 1 equiv of Ph₃P, CH₂Cl₂, 25 °C, 30 min, 84%) provided a surprisingly stable partner for the Stille cross-coupling given that the parent 2-bromomethyl pyridine is unstable to storage.

We anticipated that a Julia–Kocienski olefination³⁹ coupling would allow introduction of the requisite trans C5–C6 alkene while convergently assembling the side chain. Such an approach necessitated the preparation of the vinyl iodide **23** that constitutes the C2–C5 segment. This was accomplished through the reaction of alcohol **21**⁴⁰ with 1-phenyl-1*H*-tetrazole-5-thiol (PTSH) under Mitsunobu conditions (DEAD, Ph₃P, THF, 0 °C, 30 min, 71%) to provide thioether **22**, which was cleanly oxidized to the sulfone **23** with H₂O₂–ammonium molybdate (EtOH–THF, 25 °C, 6 h, 89%), Scheme 3.⁴¹

With this sulfone bearing the vinyl iodide in hand, the stage was set for its coupling with the C6–C13 side chain aldehyde **35**, accessible from the known alcohol **27**.¹⁷ Limitations in the reported synthesis of the alcohol **27** (problematic diastereomer separation),¹⁷ ultimately resulted in our use of a recently disclosed and more effective asymmetric anti-aldol reaction for the preparation of **30** (Scheme 4).⁴²

Thus, Whiting et al. reported¹⁷ the preparation of the aldehyde **30** in their efforts directed at the pteridin A1 side chain utilizing an asymmetric anti-aldol⁴³ of the aldehyde **25** and the chiral enolate derived from **24** providing **26** (84% ee, 23% for three steps to **27**) from which the undesired diastereomers proved difficult to separate. Consequently, we adopted a more recent preparation of aldehyde **30** disclosed by Nakao⁴² utilizing a procedure developed by Heathcock⁴⁴ enlisting 2 equiv of Bu₂BOTf to promote an anti-selective aldol addition of the Evans optically active *N*-acyl oxazolidinone **28**. As our work progressed, we also briefly examined the conditions recently disclosed by Evans⁴⁵ for promoting such direct anti-aldol additions of the optically active *N*-acyl oxazolidinones. Thus, the reaction of **31** with **25** provided **32** (MgCl₂, TMSCl, Et₃N, EtOAc, 25 °C, 24 h, 49%) in good yield and excellent diastereoselectivity. Protection of **32** (TBSCl, imidazole, DMF, 25 °C, 16 h) followed by reduction with LiBH₄ (THF, MeOH, 0 to 25 °C, 76% for two steps) provided an alternative and comparable approach to alcohol **27** which was oxidized to the aldehyde **30**.¹⁷ The aldehyde **30** was converted to alcohol **34** in two steps as previously disclosed¹⁷ and oxidized under Swern conditions to give **35** ((COCl)₂, DMSO, Et₃N, –78 °C, 99%), Scheme 5. The modified Julia coupling between **35** and **23** cleanly provided **36** (KHMDs, DME, –78 °C, 18 h, 60%) with the trans alkene isomer as the only detected product. Lithium–halogen exchange of the vinyl iodide **36** upon treatment with *n*-BuLi, followed by treatment of the vinyllithium with Bu₃SnCl provided the vinyl stannane **37** (*n*-BuLi, –78 °C, 20 min; Bu₃SnCl, 20 min, –78 to 25 °C) for the Stille coupling with **20**.

In initial studies on this final coupling reaction, it was found that only the Pd₂(dba)₃/*t*-Bu₃P catalyst system employed by Fu and coworkers was able to affect the desired reaction between the bromide **20** with the simplified vinyl stannane **50** (*vide infra*).⁴⁶ In these studies, it was found that coupling required elevated temperatures, high catalyst loading, and LiCl as an additive to achieve good conversions, and when applied to the coupling of **20** with **37** provided **38** in superb conversions (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70 °C, 18 h, 74%) without protection of the pyridyl phenol. Little or no reaction was observed at room temperature, (Ph₃P)₄Pd and (PhCN)₂PdCl₂ failed to support the reaction, DMF (100 °C, 20%) was much less effective as a solvent than dioxane, and the addition of base (NaHCO₃, *i*-Pr₂NEt) did not affect or improve the conversions. A final deprotection of the TBS ether **38** (Bu₄NF, THF, 50 °C, 12 h, 93%) provided pteridin A1 identical in all respects with properties reported for the

natural product (Scheme 5). However the magnitude of the optical rotation for synthetic **1** and that reported for natural **1** ($[\alpha]_{\text{D}}^{25} +1.8$ (c 0.1, MeOH) for synthetic **1** vs lit⁴⁷ $[\alpha]_{\text{D}}^{25} +1.0$ (c 0.1, MeOH)) was not sufficient for an unambiguous assignment of the absolute configuration. In order to more confidently address this assignment, the conversion of **1** to piericidin B1 (**2**), which exhibits a larger optical rotation, was conducted.⁴⁸ Thus, selective protection of the pyridine hydroxyl of **1** as its pivalate ester **39** (PivCl, HSO₄NBu₄, aqueous 5 N NaOH–CH₂Cl₂, 30 min, 25 °C, 92%), followed by *O*-methylation of the remaining secondary alcohol **40** (NaH, MeI, DMF, 25 °C, 1 h, 78%), and pivalate hydrolysis of **40** (*t*-BuONa, MeOH, 60 °C, 3 h, 88%) provided **2**. Synthetic piericidin B1 proved identical in all respects with properties reported for natural **2**, including its optical rotation ($[\alpha]_{\text{D}}^{25} -7.3$ (c0.2, MeOH) vs lit⁴⁸ $[\alpha]_{\text{D}}^{18} -6.5$ (c 3.2, MeOH)), thereby confirming the absolute configuration assignment for **1** and **2**.

Key Analogues

Following the completion of the total synthesis of **1** and **2**, our efforts turned to the preparation and evaluation of a series of key analogues. Throughout our studies and the handling of **1**, **2**, **17**, **19**, **20**, and **38**, only the 4-hydroxypyridine tautomer, and not the 4-pyridone tautomer, was observed even in protic solvents. Provocatively, this suggests that the ability of **1** to bind and inhibit NADH-ubiquinone reductase (Complex I) may result from mimicry of reduced coenzyme Q (hydroquinone) rather than **3** itself. Thus, modifications of the C4' hydroxyl could directly address such questions. Similarly, modifications to the side chain of the piericidins would permit the role of its substituents to be more clearly defined.

Key Side Chain Analogues

Early studies on the piericidins illustrated that simplifications in the side chain, mimicking that found in coenzyme Q, provide derivatives that maintain much of the potency of the natural products.^{18,19} However, all such work was conducted only with an assessment of Complex I inhibition and without regard for comparisons in subsequent cellular functional assays that would more specifically address their potential antitumor activity. The results of prior studies would suggest that removal of C9 and C10 substituents and/or alterations of the stereochemistry might not have a significant impact.^{18,19} Consequently, in order to further define the role of the side chain C9 and C10 stereocenters, *ent*-**1**, the inverted C10 hydroxy diastereomer **43**, and the C10 ketone **46**, along with **2**, were viewed as key structures. The unnatural enantiomer of piericidin A1, *ent*-**1** in which both the C10 and C9 stereocenters are inverted, was accessed through a sequence identical to that described for the total synthesis of **1** enlisting the enantiomer of the oxazolidinone **31**. The synthesis of the C10 hydroxy diastereomer **43**, as well as the C10 ketone **46**, required protection of the C4 pyridyl phenol after it was established that direct oxidation (Dess–Martin, PCC) of **1** itself as well as Mitsunobu inversion of the C10 hydroxy group of **1** or **39** were not straightforward. Thus, Dess–Martin oxidation (CH₂Cl₂, 25 °C, 30 min, 96%) of the pivalate ester **39**, enlisted as an intermediate in the total synthesis of piericidin B1, provided the ketone **41** (Scheme 6). Luche reduction of **41** (4 equiv of NaBH₄, 6 equiv of CeCl₃·7H₂O, EtOH, –78 to 0 °C) afforded a readily separable 1:1 mixture of the desired C10 diastereomer **42** (38%) and regenerated **39** (38%) without competitive conjugate reduction. Hydrolysis of the pivalate ester **42** (*t*-BuONa, MeOH, 60 °C, 3 h, 79%) provided **43**, the C10 diastereomer of piericidin A1. The corresponding ketone **46** was not accessible from the pivalate ester **41** requiring hydrolysis conditions that were too harsh for **41** to withstand. Consequently, piericidin A1 was converted to acetate **44** (AcCl, HSO₄NBu₄, aqueous 5 N NaOH–CH₂Cl₂, 25 °C, 30 min, 93%), a key analogue of **1** in its own right, which was oxidized to the ketone **45** (Dess–Martin periodinane, CH₂Cl₂, 25 °C, 30 min, 89%). Mild hydrolysis of **45**, also an interesting analogue of **1**, provided the ketone **46** (NaHCO₃, MeOH, 4 days, 71%).

Finally, two analogues containing simplified side chains were prepared for comparison. The first, **51**, incorporates the farnesyl side chain found in coenzyme Q (**3**). Thus, the vinyl stannane **48**, accessed from the known vinyl iodide **47**⁴⁹ (*n*-BuLi, -78°C , 20 min; Bu₃SnCl, 20 min, -78 to 25°C) was coupled with **20** using the conditions developed for **1** (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70°C , 18 h) to provide **51** (76%), an analogue first described in the studies of Rapoport (Scheme 7).¹⁸ In addition, **52** incorporating a truncated side chain was also prepared. Coupling of the vinyl stannane **50**, derived from the known vinyl iodide **49**⁵⁰ (*n*-BuLi, -78°C , 20 min; Bu₃SnCl, 20 min, -78 to 25°C) afforded **52** (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70°C , 18 h, 68%) which was deprotected (Bu₄NF, THF, 25°C , 8 h, 83%) to afford **53**.

Key Pyridyl Analogues

A key objective of the analogue assessment was to probe the role of the pyridyl C4' hydroxyl group within **1**. This was addressed both by its selective protection (i.e., **44** and **45**) as well as with the total synthesis of 4'-deshydroxypiericidin A1 (**59**). Thus, complementing the availability of the labile C4' acetates **45** and **46** of piericidin A1 and its C10 ketone, the hydrolytically stable C4' methyl ether **54** was prepared by selective methylation of piericidin A1 (MeI, HSO₄NBu₄, aqueous 5 N NaOH–CH₂Cl₂, 25°C , 2 h, 90%), Scheme 8. Similarly, C4' phenol methylation of **51**, bearing the farnesyl side chain, was also conducted providing **55** (MeI, HSO₄NBu₄, aqueous 5 N NaOH–CH₂Cl₂, 25°C , 2 h, 90%).

More significantly, C4'-deshydroxypiericidin A1 (**58**) was prepared by total synthesis for examination. The availability of the pyridyl alcohol **15**, its one-step conversion to the Stille cross-coupling substrate **56** (1 equiv of CBr₄, 1 equiv of Ph₃P, CH₂Cl₂, 25°C , 30 min, 79%), and its convergent coupling with **37**, constituting the fully functionalized piericidin A1 side chain, provided **57** (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70°C , 3 h, 66%) in two steps from materials available from the total synthesis of **1** and **2** (Scheme 9). A final silyl ether deprotection of **57** (HF–pyridine, 25°C , 48 h, 54%) provided **58**. Similarly, the C4'-deshydroxy analogue **59** bearing the simplified farnesyl side chain was prepared by Stille coupling of **56** with **48** to provide **59** (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70°C , 3 h, 59%) in a single step (Scheme 9). Thus, an attribute of the route to piericidin that emerged from the failure of **6** to productively provide the fully substituted pyridyl core was the generation of **15** and the post cycloaddition introduction of the C4' hydroxyl group. Its availability, like that of a subsequent pyridyl core (**65**, Scheme 10), provided ready access to the corresponding C4'-deshydroxypiericidin A1 analogues.

Preceding studies with simplified structures implicated the C5' methyl group as a key pyridyl substituent although studies to probe its role with an intact piericidin structure have not, to our knowledge, been conducted.¹⁹ Since it represents a key substituent also found on the quinone of coenzyme Q, a pronounced impact of this substituent might well help establish the apparent structural relationship between the piericidin pyridyl core and the coenzyme Q quinone/hydroquinone subunit. Consequently, the synthetic approach was modified to access this alternatively substituted pyridine core. This entailed conversion of diethyl oxalate to β -keto ester **60** (CH₂=CHMgBr, -78°C) followed by oxime formation to provide **61** (NH₂OH–HCl, EtOH, 18 h, 45% for 2 steps).³³ Treatment of the oxime **61** with methylsulfinyl chloride and Et₃N (CH₂Cl₂, 0°C , 20 min) afforded the *N*-sulfonyl-1-azadiene **62** which smoothly participated in the Diels–Alder reaction with **8** to yield cycloadduct **63** (toluene, 50°C , 18 h, 51% for 2 steps from **61**). Aromatization upon treatment of **63** with BF₃·OEt₂ (CH₂Cl₂, 0°C , 1 h, 88%) afforded the ester **64** which was reduced with DIBALH (CH₂Cl₂, 0°C , 1 h, 94%) to provide alcohol **65** that was protected as the TIPS ether **66** (TIPSCl, imidazole, DMF, 25°C , 18 h, 88%). Subjection of **66** to the borylation/oxidation sequence afforded a mixture of the *C*- and *O*-silylated products **67** and **68** (5 equiv of BuLi, 6 equiv of B(OMe)₃, 1 h, 37% (**67**) and 35% (**68**)). This mixture of products does not seem to be a result of partial Brook

rearrangement of **68** to **67** in the course of the basic aqueous work-up as both products are present by TLC prior to work-up. Moreover extended exposure (18 h) to the aqueous work-up conditions does not change the ratio of the products, suggesting the product mixture arises in the course of the reaction. Deprotection of the **67** and **68** mixture (Bu₄NF, THF, 25 °C, 18 h, 69%) afforded **70**, and its subsequent conversion to bromide **71** (1 equiv of CBr₄, 1 equiv of PPh₃, CH₂Cl₂, 76%) proceeded cleanly. In order to access the corresponding 4'-deshydroxy-5'-desmethyl derivatives, **65** was similarly converted to the bromide **69** (1 equiv of CBr₄, 1 equiv of PPh₃, CH₂Cl₂, 81%).

With heterobenzylic bromides **69** and **71** in hand, we were positioned to access 5'-desmethyl and 4'-deshydroxy-5'-desmethyl analogues bearing the piericidin side chain as well as the simplified farnesyl side chain. As such, Stille coupling of **71** with **37** afforded **72** (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70 °C, 18 h, 62%) which was deprotected (HF–pyridine, 25 °C, 48 h, 87%) to afford 5'-desmethylpiericidin A1 (**73**). Similarly and without optimization, 4'-deshydroxy-5'-desmethylpiericidin A1 (**75**) was accessed through coupling of **69** and **37** (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70 °C, 3 h, 49%) followed by deprotection to give **75** (HF–pyridine, 25 °C, 48 h, 73%), and the corresponding farnesyl side chain bearing analogues **76** and **77** were accessed through coupling **71** with **48** (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70 °C, 18 h, 58%) and **69** with **48** (Pd₂(dba)₃, *t*-Bu₃P, LiCl, dioxane, 70 °C, 3 h, 54%), respectively.

Compound Assessments

The natural products and the key analogues were examined for inhibition of Complex I as measured against submitochondrial particles⁵¹ as well as for growth inhibition in a functional, cell-based cytotoxic assay enlisting a mouse leukemia cell line (L1210), Table 1. At the onset, it should be noted that the latter structure–activity relationship (SAR) data need not follow that of the target-based assay of Complex I inhibition because of the additional features such cell-based assays might select for (e.g., cell permeability). Moreover, it is not yet established that the cytotoxic activity of the piericidins is derived from Complex I inhibition and, as such, the data derived from the cell-based assay may reflect other or additional unidentified targets. Consequently, the trends that emerged from the evaluation of compounds in the two assays are discussed separately below and qualified as to their relationship.

As previously disclosed, piericidin A1 proved to be a potent Complex I inhibitor (**1**, IC₅₀ = 3.7 nM) being slightly more potent in our assay than piericidin B1 (**2**, IC₅₀ = 5.1 nM) and rotenone (**4**, IC₅₀ = 5.0 nM). Small modifications in the side chain had little impact on this activity. Thus, *O*-methylation of the C10 alcohol (**2**, piericidin B1, IC₅₀ = 5.0 nM), its conversion to a ketone (**46**, IC₅₀ = 6.3 nM), and the inversion of the C10 alcohol stereochemistry with **43** (IC₅₀ = 8 nM) resulted in modest ≤ 2-fold reductions in potency. More remarkably, *ent*-piericidin A1 (*ent*-**1**, IC₅₀ = 8.8 nM), where both the C9 methyl and C10 hydroxy are inverted, proved to be only 2.5-fold less potent than the natural product. Consistent with these observations and with past studies,¹⁸ replacement of the side chain with the simplified farnesyl side chain lacking these substituents and stereocenters provided an analogue **51** (IC₅₀ = 3.8 nM) that was not distinguishable from **1** itself. Nonetheless, the importance of the presence of the side chain is clear with **53** (IC₅₀ = 10,000 nM) where the removal of the C5–C16 segment resulted in a 10³–10⁴ fold loss in activity. In total, these observations are consistent with piericidin mimicking coenzyme Q leading to predicable simplifications in the inhibitor structures.

However, as noted below, these simplifications and trends do not similarly track with the relative cytotoxic potencies of the analogues. Rather, the cytotoxic potency of the analogues dropped progressively with the significance of the structural changes in the side chain. Whereas piericidin B1 (**2**, IC₅₀ = 6 nM) was equipotent with piericidin A1 (**1**, IC₅₀ = 5 nM), the C10

alcohol diastereomer **43** (IC_{50} = 75 nM), the C10 ketone **46** (IC_{50} = 600 nM), and *ent*-**1** (IC_{50} = 700 nM) proved to be 15–150 fold less potent. Similarly, **51** (IC_{50} = 95 nM) bearing the simplified farnesyl side chain was found to be 20-fold less potent than **1**, and **53** (IC_{50} = 6000 nM), lacking the C5–C16 segment of the side chain, was expectedly 1000-fold less potent. This would suggest that either the cytotoxic activity of the compounds is not derived solely from Complex I inhibition, or that the side chain substituents and their stereochemistry contribute significantly to **1** reaching its biological target in the functional cellular assay. The impact of the pyridyl C4' hydroxyl group proved just as interesting, especially on the inhibition of Complex I and in light of the potential coenzyme Q structural relationship. Whereas its acetylation (**44**, IC_{50} = 24 nM; **45**, IC_{50} = 26 nM) or methylation (**54**, IC_{50} = 130 nM) led to 7-fold and 35-fold reductions in potency, its removal altogether with 4'-deshydroxypiericidin (**58**, IC_{50} = 10 nM) had a surprisingly modest impact reducing the Complex I inhibition only 3-fold. In marked contrast, *O*-methylation of the C4' phenol (**55**, IC_{50} = 750 nM) as well as the removal of the C4' phenol (**59**, IC_{50} = 400 nM) in the analogues bearing the simplified farnesyl side chain reduced Complex I inhibition >100-fold. These latter studies support the contention that piericidin A1 mimics the coenzyme Q hydroquinone and that the C4' hydroxy group is central to its activity, whereas the surprisingly potent inhibition by 4'-deshydroxypiericidin A1 (**58**) suggests that the natural products side chain substituents may somehow compensate for losses in binding affinity that result from modifications in the pyridyl core.

With a notable exception, this modification or removal of the pyridyl C4' hydroxy group substantially reduced the cytotoxic activity of the compounds. Thus *O*-methylation of the piericidin C4' phenol (**54**, IC_{50} = 800 nM) or its removal (**58**, IC_{50} = 800 nM) resulted in 200-fold reductions in cytotoxic activity and the impact of these changes on the simplified analogues **55** (IC_{50} = 8000 nM) and **59** (IC_{50} = 5000 nM) bearing the farnesyl side chain was an even greater 1000-fold loss in activity. The only exceptions to these generalizations were the C4' *O*-acetyl derivatives **44** (IC_{50} = 3 nM) and **45** (IC_{50} = 90 nM). Thus, C4'-*O*-acetyl piericidin A1 (**44**) was found to be equally potent, or perhaps slightly more potent, than **1** itself. Although surprising on the surface, this most likely is the result of *O*-acetate hydrolysis in the cellular assay releasing the natural product itself. Similarly, **45** was found to be roughly six-fold more potent than the free phenol **46**, but still nearly 20-fold less potent than **1**.

The C5' methyl group of piericidin had a similar remarkable impact on the molecules properties. Its removal with 5'-desmethylpiericidin A1 (**73**, IC_{50} = 4.0 nM) had little or no impact on Complex I inhibition, whereas its removal in the analogue **76** (IC_{50} = 110 nM) bearing the farnesyl side chain reduced Complex I inhibition 30-fold relative to both **51** (IC_{50} = 3.8 nM) or **1** (IC_{50} = 3.7 nM). Just as remarkable, removing both the C4' hydroxyl and C5' methyl groups with **75** (IC_{50} = 9.0 nM) only reduced the Complex I inhibition ca. 2-fold relative to piericidin A1 itself, whereas this double modification in the analogue **77** bearing the farnesyl side chain resulted in compound that was >500-fold less potent than **1** or **51**. As such, the surprisingly potent activity of **73** and especially **75** suggests that the natural product side chain substituents (vs the farnesyl side chain) somehow compensates for losses in binding affinity that result from modifications in the pyridyl core.

In an interesting contrast, this removal of the pyridyl C5' methyl group led to an ca. ≥ 500 -fold loss in cytotoxic potency. Thus, 5'-desmethylpiericidin A1 (**73**, IC_{50} = 2,500 nM) proved to be 500-fold less active than the natural product. Removing both the C4' hydroxy group as well as the C5' methyl group led to a compound that was even less potent (**75**, IC_{50} = 4,000 nM). Significantly, this removal of the C5' methyl group had an even larger impact on the cytotoxic activity than the critical C4' hydroxy group. Incorporating these structural changes into analogues bearing the farnesyl side chain (**76** and **77**) led to even further reductions in the cytotoxic activity (IC_{50} = 5,500 and 20,000 nM, respectively).

Clear from these comparisons is the observation that the side chain substituents of piericidin A1 may impact Complex I inhibition and do so most productively and significantly when key structural features of the pyridyl core are removed. Similarly, they enhance the cytotoxic activity of the compounds, but their impact seems to be most significant if the pyridyl core of **1** is intact. In contrast, the pyridyl C4' hydroxy group as well as the C5' methyl substituent appear more central to the molecules properties since their modification or removal leads to reductions in Complex I inhibition and even more significant reductions in the cytotoxic activity where the intact pyridyl core appears most essential. The exception to this generalization is the unusually potent Complex I inhibition by **58**, **73**, and **75** where the piericidin A1 side chain (but not farnesyl) appears to compensate for their removal (Figure 4). Significantly, the series of analogues bearing the farnesyl side chain exhibit trends consistent with expectations of a simple coenzyme Q mimic where both the C4' hydroxyl group and the C5' methyl group each increase either the Complex I inhibition or L1210 cytotoxicity approximately 30–100 fold with the former target-based assay (Complex I) assay exhibiting IC₅₀'s approximately 10-fold lower than the cell-based (L1210) assay. In marked contrast, the series bearing the piericidin A1 side chain exhibited much smaller 1–2.5 fold losses in Complex I activity with removal of either the C4' hydroxyl or C5' methyl group, while experiencing even greater 200–500 losses in cytotoxic activity in the cellular assay. Even so, this latter series remained roughly 10-fold more potent (2–20 fold) than the farnesyl series in the cellular assay (L1210) and was typically much more potent (1–200 fold) against Complex I itself. Whether the lack of direct correlation between the two series in the two assays reflects the molecules ability to access Complex I in the cellular assay, the more subtle distinctions between multiple binding sites on Complex I and their biological consequences, or even the intervention of additional biological targets, remain to be established.

Conclusion

An effective and convergent total synthesis of piericidin A1 and B1 was developed which features a facile *N*-sulfonyl-1-azadiene inverse electron demand Diels–Alder conducted at 50 °C to access the highly functionalized pyridyl core. The side chain was prepared enlisting an asymmetric anti-aldol reaction to install the C9 and C10 absolute stereochemistry, and a trans-selective Julia–Kocienski C5–C6 olefination to convergently assemble the side chain. A surprisingly effective and strategic late stage Stille cross-coupling reaction of the pyridyl core (a heterobenzylic bromide) with the fully functionalized side chain was used to complete the synthesis. Not only did this serve as the first disclosed total synthesis¹⁴ of a member of this natural product class permitting an unambiguous assignment of the unresolved absolute stereochemistry, but it did so by an approach that permitted access to structural analogues in which either half of the molecule could be divergently altered at a late stage.

Thus, the studies were extended to include total syntheses of *ent*-piericidin A1 in which both the C9 and C10 stereocenters were inverted, 4'-deshydroxypiericidin A1 (**58**) and 5'-desmethypiericidin (**73**) each lacking a key substituent of the putative quinone mimic, 4'-deshydroxy-5'-desmethypiericidin A1 (**75**), and the simplified analogues **51**, **59**, **76**, and **77** bearing an unfunctionalized farnesyl side chain linked to either the authentic, 4'-deshydroxypyridyl, 5'-desmethylpyridyl, or 4'-deshydroxy-5'-desmethylpyridyl core. The evaluation of these key analogues, along with those derived from further functionalization of the analogues and **1**, permitted a scan of the key structural features providing new insights into the role of substituents found on both the pyridyl core as well as the side chain.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

We gratefully acknowledge the financial support of the National Institutes of Health (D.L.B. CA 42056 and T.Y. GM 33712) and the Skaggs Institute for Chemical Biology. MJS is a Skaggs Fellow. FAR acknowledges the American Cancer Society for a postdoctoral fellowship.

References

1. Takahashi N, Suzuki A, Tamura S. *J. Am. Chem. Soc* 1965;87:2066. [PubMed: 14290282]
2. Nelson, DL.; Cox, MM. *Lehninger Principles of Biochemistry*. Worth; New York: 2000. Chapter 19
3. Esposti MD. *Biochim. Biophys. Acta* 1998;1364:222. [PubMed: 9593904]
4. Yoshida S, Yoneyama K, Shiraishi S, Watanabe A, Takahashi N. *Agric. Biol. Chem* 1977;41:849.
5. Kimura K, Takahashi H, Miyata N, Yoshihama M, Uramoto M. *J. Antibiot* 1996;49:697. [PubMed: 8784434]
6. Matsumoto M, Mogi K, Nagaoka K, Ishizeki S, Kawahara R, Nakashima T. *J. Antibiot* 1987;40:149. [PubMed: 3570963]
7. Ahn SC, Kim BY, Oh WK, Kang DO, Heo GY, Kim MS, Lee MS, Ahn JS. *J. Antibiot* 2002;55:1013. [PubMed: 12546423]
8. Kitaura, N.; Shirata, K.; Niwano, M.; Mimura, M.; Takahara, Y. *Chem. Abstr Japanese Patent* 05339156 A2, 1993. 1994. p. 208590
9. Udeani GO, Gerhauser C, Thomas CF, Moon RC, Kosmeder JK, Kinghorn AD, Moriarty RM, Pezzuto JM. *Cancer Res* 1997;57:3424. [PubMed: 9270008]and references cited therein
10. Fang N, Casida JE. *Proc. Natl. Acad. Sci. USA* 1998;95:3380. [PubMed: 9520374]
11. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP. *J. Biol. Chem* 2003;278:8516. [PubMed: 12496265]
12. Kushnareva Y, Murphy AN, Andreyev A. *Biochem. J* 2002;368:545. [PubMed: 12180906]
13. Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. *J. Neurosci* 2003;23:10756. [PubMed: 14645467]
14. Schnermann MJ, Boger DL. *J. Am. Chem. Soc* 2005;127:15704. [PubMed: 16277503]
15. Keaton KA, Phillips AJ. *J. Am. Chem. Soc* 2006;128:408. [PubMed: 16402817]
16. (a) Ono M, Yoshida N, Kokubu Y, Sato E, Akita H. *Chem. Pharm. Bull* 1997;45:1428. (b) Ono M, Yoshida N, Akita H. *Chem. Pharm. Bull* 1997;45:1745.
17. Cox CM, Whiting DA. *J. Chem. Soc. Perkin Trans* 1991;1:1901.
18. (a) Schmidtchen FP, Rapoport H. *J. Am. Chem. Soc* 1977;99:7014. [PubMed: 561812] (b) Gutman M, Klaitchko S. *FEBS Lett* 1976;67:348. [PubMed: 986952]
19. Yoshida S, Takahashi N. *Heterocycles* 1978;10:425.
20. Chung KH, Cho KY, Asami. Y; Takahashi N, Yoshida S. *Z. Naturforsch* 1989;44c:609.
21. Takahashi N, Suzuki A, Kimura Y, Miyamoto S, Tamura S. *Tetrahedron Lett* 1967;8:1961. [PubMed: 6043699]
22. Yoshida S, Shiraishi S, Fujita K, Takahashi N. *Tetrahedron Lett* 1975;16:1863.
23. Jansen R, Hofle G. *Tetrahedron Lett* 1983;24:5485.
24. (a) Boger DL, Corbett WL, Wiggins JM. *J. Org. Chem* 1990;55:2999. (b) Boger DL, Corbett WL, Curran TT, Kasper AM. *J. Am. Chem. Soc* 1991;113:1713. (c) Boger DL, Kasper AM. *J. Am. Chem. Soc* 1989;111:1517. (d) Boger DL, Curran TT. *J. Org. Chem* 1990;55:5439. (e) Clark RC, Pfeiffer SS, Boger DL. *J. Am. Chem. Soc* 2006;128:2587. [PubMed: 16492042] (f) Boger DL. *Tetrahedron* 1983;39:2869. Reviews: Boger DL. *Chem. Rev* 1986;86:781. Boger DL. *Chemtracts: Org. Chem* 1996;9:149.
25. Scheeren JW, Staps RJFM, Nivard RJF. *Rec. Trav. Chim* 1973;92:11.
26. (a) Boger DL, Cassidy KC, Nakahara S. *J. Am. Chem. Soc* 1993;115:10733. (b) Boger DL, Hüter O, Mbiya K, Zhang M. *J. Am. Chem. Soc* 1995;117:11839. (c) Boger DL, Hong J. *J. Am. Chem. Soc* 1998;120:1218. (d) Boger DL, Blagg BSJ. *Tetrahedron* 2002;58:6343.
27. Boger DL, Brotherton CE. *J. Org. Chem* 1984;49:4050.

28. Friedrich T, Van Heek P, Leif H, Ohnishi T, Forche E, Kunze B, Jansen R, Trowitzsch-Kienast W, Hofle G, Reichenbach H, Weiss H. *Eur. J. Biochem* 1994;219:691. [PubMed: 8307034]
29. Okun JG, Lummen P, Brandt U. *J. Biol. Chem* 1999;274:2625. [PubMed: 9915790]
30. Ramsay RR, Krueger MJ, Youngster SK, Gluck MR, Casida JE, Singer TP. *J Neurochem* 1991;56:1184. [PubMed: 2002336]
31. Lummen P. *Biochim. Biophys. Acta* 1998;1364:287. [PubMed: 9593947]
32. Synthesis described in supporting information.
33. Rambaud M, Bakasse M, Duguay G, Villieras J. *Synthesis* 1988:564.
34. Brown C, Hudson RF, Record KAF. *J. Chem. Soc., Perkin Trans* 1978;2:822.
35. The coordinates of the X-ray structures of **13** (CCDC 600039) and **17** (CCDC 600040) have been deposited with the Cambridge Crystallographic Data Centre.
36. Boger DL, Nakahara S. *J. Org. Chem* 1991;56:880.
37. Trecourt F, Mallet M, Mongin F, Queguiner G. *J. Org. Chem* 1994;59:6173.
38. Wright A, West R. *J. Am. Chem. Soc* 1974;96:3214.
39. Blakemore PR, Cole WJ, Kocienski PJ, Morley A. *Synlett* 1998:26.
40. Ndibwani A, Lamothe S, Guay D, Plante R, Soucy P, Goldstein S, Deslongchamps P. *Can. J. Chem* 1993;71:695.
41. Ahmed A, Hoegenauer EK, Enev VS, Hanbauer M, Kaehlig H, Ohler E, Mulzer J. *J. Org. Chem* 2003;68:3026. [PubMed: 12688769]
42. Nakao Y, Yoshida WY, Takada Y, Kimura J, Yang L, Mooberry SL, Scheuer PJ. *J. Nat. Prod* 2004;67:1332. [PubMed: 15332851]
43. Gennari C, Bernardi A, Colombo L, Scolastico C. *J. Am. Chem. Soc* 1985;107:5812.
44. Danda H, Hansen MM, Heathcock CH. *J. Org. Chem* 1990;55:173.
45. Evans DA, Tedrow JS, Shaw JT, Downey CW. *J. Am. Chem. Soc* 2002;124:392. [PubMed: 11792206]
46. Littke AF, Schwarz L, Fu GC. *J. Am. Chem. Soc* 2002;124:6343. [PubMed: 12033863]
47. Urakawa A, Sasaki T, Yoshida K, Otani T, Lei Y, Yun W. *J. Antibiot* 1996;49:1052. [PubMed: 8968401]
48. Takahashi N, Suzuki A, Kimura Y, Miyamoto S, Tamura S, Mitsui T, Fukami J. *Agric. Biol. Chem* 1968;32:1115.
49. Svatos A, Urbanova K, Valterova I. *Collect. Czech. Chem. Commun* 2002;67:83.
50. Andresen G, Eriksen AB, Dalhus B, Gunderson LL, Rise F. *J. Chem. Soc., Perkin Trans* 2001;1:1662.
51. Matsuno-Yagi A, Hatefi Y. *J. Biol. Chem* 1985;260:14424.

Figure 1.
Structure of Piericidin A1 and B1

Figure 2.
Retrosynthetic Analysis

Scheme 1.

Scheme 2.

Figure 3.
X-ray crystal structures of **13** and **17**

Scheme 3.

Scheme 4.

Scheme 5.
Synthesis of Piericidin A1 and B1

Scheme 6.
 Synthesis of Analogues **43**, **44**, **45** and **46**

Scheme 7.
Synthesis of Analogues **51** and **53**

Scheme 8.
Synthesis of Analogues **54** and **55**

Scheme 9.
Synthesis of Analogues **57** and **59**

Scheme 10.

Scheme 11.
 Synthesis of Analogues **73**, **75**, **76**, and **77**

Compd.	R^1	R^2	Complex I IC_{50} , nM	L1210 IC_{50} , nM
51	OH	CH_3	3.8	95
55	OCH_3	CH_3	750	8,000
59	H	CH_3	400	5,000
76	OH	H	110	5,500
77	H	H	2,200	20,000

Compd.	R^1	R^2	Complex I IC_{50} , nM	L1210 IC_{50} , nM
1	OH	CH_3	3.7	5
54	OCH_3	CH_3	130	800
58	H	CH_3	10	800
73	OH	H	4.0	2,500
75	H	H	9.0	4,000

Figure 4.
Key Comparisons

Table 1

Compound Assessments

Compd.	Mitochondrial Complex I Inhibition IC ₅₀ (nM) ^a	L1210 IC ₅₀ (nM) ^b
1	3.7	5
<i>ent-1</i>	8.8	700
2	5.1	6
4	5.0	20
43	8	75
44	24	3
45	26	90
46	6.3	600
51	3.8	95
53	10,000	6,000
54	130	800
55	750	8,000
58	10	800
59	400	5,000
73	4.0	2,500
75	9.0	4,000
76	110	5,500
77	2,200	20,000

^a Tests performed on bovine submitochondrial particles (SMP).
Concentrations required for half-maximal inhibition, average of 1–2 determinations.

^b L1210 Cytotoxic activity, average of 1–2 determinations performed in triplicate.